Pulmonary Arterial Hypertension Pipeline 2025

DelveInsight's "Pulmonary Arterial Hypertension Pipeline Insight 2025" report delivers extensive analysis on over 55 companies and more than 55 pipeline drugs in the Pulmonary Arterial Hypertension treatment landscape. It features in-depth profiles of Pulmonary Arterial Hypertension pipeline drugs, covering both clinical and nonclinical development phases. Furthermore, it assesses therapeutics by product category, development stage, delivery route, and molecular structure. It also identifies discontinued pipeline products in this domain.

Discover the newest medications and treatment avenues in the Pulmonary Arterial Hypertension Pipeline. Explore DelveInsight's thorough report now! @ Pulmonary Arterial Hypertension Pipeline Outlook

Key Takeaways from the Pulmonary Arterial Hypertension Pipeline Report

• On September 3, 2025, the International University of Health and Welfare launched a trial to assess the effectiveness of satralizumab in patients with pulmonary arterial hypertension (PAH) showing an immune-responsive profile, characterized by serum interleukin-6 (IL-6) levels ≥ 2.73 pg/mL, who have not responded adequately to current treatments.

• DelveInsight's Pulmonary Arterial Hypertension Pipeline report showcases a dynamic field with over 55 active contributors developing more than 55 pipeline treatments for Pulmonary Arterial Hypertension care.

• The top Pulmonary Arterial Hypertension Companies include Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.

• Promising Pulmonary Arterial Hypertension Pipeline Therapies include TPN171H, Tadalafil, Bosentan, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept, Macitentan, Treprostinil Palmitil, and others.

Gain insights into Pulmonary Arterial Hypertension Clinical Trials, emerging treatments, and key companies via DelveInsight @ Pulmonary Arterial Hypertension Treatment Drugs

Pulmonary Arterial Hypertension Emerging Drugs Profile

• Sotatercept: Acceleron Pharma Sotatercept is a pioneering therapeutic fusion protein consisting of the extracellular domain of human activin receptor type IIA, linked to the Fc domain of human immunoglobulin G1 (IgG1). It balances the growth-promoting activin growth differentiation factor pathway and the growth-inhibiting BMP pathway by acting as a ligand trap for the TGF-β superfamily. The United States Food and Drug Administration (FDA) has awarded Orphan Drug designation and Breakthrough Therapy designation to sotatercept for PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for PAH treatment. Sotatercept is in Phase III clinical trials for PAH.

• LIQ861: Liquidia Technologies LIQ861 is an experimental, inhaled dry powder formulation of treprostinil developed using the Company's innovative PRINT technology, aimed at improving deep-lung delivery of treprostinil in PAH patients via a portable, palm-sized dry powder inhaler. Liquidia has resubmitted the New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for pulmonary arterial hypertension (PAH) management.

The Pulmonary Arterial Hypertension Pipeline Report Provides Insights into

• The report furnishes comprehensive details on organizations advancing therapies for Pulmonary Arterial Hypertension, including the total treatments each company is developing.

• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Pulmonary Arterial Hypertension management.

• Pulmonary Arterial Hypertension Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.

• Pulmonary Arterial Hypertension Drugs in progress, sorted by development phase, administration route, target receptor, single or combined therapy, unique action mechanisms, and molecular category.

• Comprehensive review of partnerships (corporate alliances and academic ties), licensing arrangements, and funding information to drive future growth in the Pulmonary Arterial Hypertension market.

Explore innovative treatments and clinical trials in the Pulmonary Arterial Hypertension Pipeline. Obtain DelveInsight's detailed report today! @ New Pulmonary Arterial Hypertension Drugs

Pulmonary Arterial Hypertension Companies Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.

Pulmonary Arterial Hypertension pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

• Molecule Type

Pulmonary Arterial Hypertension Products have been categorized under various Molecule types such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

Learn about emerging Pulmonary Arterial Hypertension drugs, pipeline advancements, and key companies with DelveInsight's expert analysis @ Pulmonary Arterial Hypertension Market Drivers and Barriers

Scope of the Pulmonary Arterial Hypertension Pipeline Report

• Coverage- Global

• Pulmonary Arterial Hypertension Companies- Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others.

• Pulmonary Arterial Hypertension Pipeline Therapies- TPN171H, Tadalafil, Bosentan, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept, Macitentan, Treprostinil Palmitil, and others.

• Pulmonary Arterial Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Pulmonary Arterial Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's comprehensive Pulmonary Arterial Hypertension Pipeline report now! @ Pulmonary Arterial Hypertension Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction

2. Executive Summary

3. Pulmonary Arterial Hypertension: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Pulmonary Arterial Hypertension - DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Sotatercept: Acceleron Pharma

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. GB-002: Gossamer Bio

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I)

14. Apabetalone: Resverlogix

15. Drug profiles in the detailed report.....

16. Preclinical/Discovery Stage Products

17. R107: Radikal Therapeutics

18. Drug profiles in the detailed report.....

19. Inactive Products

20. Pulmonary Arterial Hypertension Key Companies

21. Pulmonary Arterial Hypertension Key Products

22. Pulmonary Arterial Hypertension- Unmet Needs

23. Pulmonary Arterial Hypertension- Market Drivers and Barriers

24. Pulmonary Arterial Hypertension- Future Perspectives and Conclusion

25. Pulmonary Arterial Hypertension Analyst Views

26. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us 

Kanishk

kkumar@delveinsight.com